A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 19 Jul 2023 Number of treatment arms have been increased from 4 to 5 by the addition of "Experimental: Double-blind Curtailed Herold Regimen" arm.
- 21 Feb 2013 Planned number of patients changed to 538.
- 21 Feb 2013 New trial record